Albert David Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts less than Nifty Microcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited reported audited financial results for Q4 and FY ended March 31, 2026. Total income stood at Rs. 34,105.14 lakhs, down from Rs. 37,534.87 lakhs in the previous year. Profit before tax dropped sharply to Rs. 52.49 lakhs from Rs. 2,522.77 lakhs, resulting in a net loss of Rs. -149.47 lakhs for the year versus a profit of Rs. 1,720.08 lakhs in FY25. The Board appointed Mr. Amit Mahla as CEO effective May 12, 2026, filling a vacancy created by the resignation of Mr. Umesh Manohar Kunto (who stepped down as MD & CEO on December 18, 2025). The company recommended a final dividend of Rs. 5 per share (50%) subject to shareholder approval. Statutory auditors L.B. Jha & Co. issued an unmodified opinion, and internal auditor PwC and cost auditor S. Gupta & Co. were reappointed for FY27.
The significant decline in profitability is concerning for investors. However, the appointment of an experienced pharmaceutical executive and the continued dividend payment provide some stability. The large gap between CEO resignation (Dec 2025) and replacement appointment (May 2026) may raise governance questions.